Jaguar Animal Health, Inc. (NASDAQ:JAGX) Short Interest Update

Posted by Anthony Miller on Mar 17th, 2026

Jaguar Animal Health, Inc. (NASDAQ:JAGX – Get Free Report) was the recipient of a significant decline in short interest in the month of February. As of February 27th, there was short interest totaling 327,563 shares, a decline of 15.1% from the February 12th total of 386,035 shares. Currently, 9.5% of the company’s shares are short sold. Based on an average daily volume of 392,756 shares, the short-interest ratio is currently 0.8 days. Based on an average daily volume of 392,756 shares, the short-interest ratio is currently 0.8 days. Currently, 9.5% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

JAGX has been the topic of several research reports. Wall Street Zen downgraded Jaguar Animal Health to a “strong sell” rating in a report on Friday, January 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Jaguar Animal Health in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $60.00.

Get Our Latest Analysis on JAGX

Jaguar Animal Health Stock Down 4.6%

Shares of JAGX traded down $0.02 during trading hours on Tuesday, hitting $0.48. The company had a trading volume of 452,980 shares, compared to its average volume of 560,222. The company has a current ratio of 0.81, a quick ratio of 0.52 and a debt-to-equity ratio of 4.08. The company has a market capitalization of $1.80 million, a PE ratio of -0.01 and a beta of 0.03. Jaguar Animal Health has a one year low of $0.46 and a one year high of $15.48. The company’s fifty day moving average price is $0.72 and its two-hundred day moving average price is $1.33.

About Jaguar Animal Health

(Get Free Report)

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.